Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Arnold M, Ferlay J, Van Berge Henegouwen MI, et al. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut. 2020;69:1564–71.

Article  PubMed  Google Scholar 

Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75.

Article  PubMed  PubMed Central  Google Scholar 

Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71.

Article  CAS  PubMed  Google Scholar 

Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449–62.

Article  CAS  PubMed  Google Scholar 

van Rossum PSN, Mohammad NH, Vleggaar FP, et al. Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends. Nat Rev Gastroenterol Hepatol. 2018;15(4):235–49.

Article  PubMed  Google Scholar 

Guo JH, Teng GJ, Zhu GY, et al. Self-expandable esophageal stent loaded with 125I seeds: initial experience in patients with advanced esophageal cancer. Radiology. 2008;247(2):574–81.

Article  PubMed  Google Scholar 

Zhu HD, Guo JH, Mao AW, et al. Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial. Lancet Oncol. 2014;15(6):612–9.

Article  CAS  PubMed  Google Scholar 

Dai Z, Zhou D, Hu J, et al. Clinical application of iodine-eluting stent in patients with advanced esophageal cancer. Oncol Lett. 2013;6(3):713–8.

Article  PubMed  PubMed Central  Google Scholar 

Sur RK, Donde B, Levin VC, Mannell A. Fractionated high dose rate intraluminal brachytherapy in palliation of advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 1998;40(2):447–53.

Article  CAS  PubMed  Google Scholar 

Sur RK, Levin CV, Donde B, Sharma V, Miszczyk L, Nag S. Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma–an International Atomic Energy Agency study. Int J Radiat Oncol Biol Phys. 2002;53(1):127–33.

Article  PubMed  Google Scholar 

Homs MY, Steyerberg EW, Eijkenboom WM, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial.

Bergquist H, Wenger U, Johnsson E, et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus. 2005;18(3):131–9.

Article  CAS  PubMed  Google Scholar 

Amdal CD, Jacobsen AB, Sandstad B, et al. Palliative brachytherapy with or without primary stent placement in patients with oesophageal cancer, a randomised phase III trial. Radiother Oncol. 2013;107(3):428–33.

Article  PubMed  Google Scholar 

Welsch J, Kup PG, Nieder C, Khosrawipour V, Bühler H, Adamietz IA, Fakhrian K. Survival and symptom relief after palliative radiotherapy for esophageal cancer. J Cancer. 2016;7(2):125–30. https://doi.org/10.7150/jca.13655.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenblatt E, Jones G, Sur RK, et al. Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: a prospective multi-centre randomized trial of the International Atomic Energy Agency. Radiother Oncol. 2010;97(3):488–94.

Article  PubMed  Google Scholar 

Sur R, Donde B, Falkson C, et al. Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer. Brachytherapy. 2004;3(4):191–5.

Article  PubMed  Google Scholar 

• Adamson D, Byrne A, Porter C, et al. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol. 2021;6(4):292–303. This reference is of importance because it is the multicenter open-label, phase III trial demonstrated that patients with advanced esophageal cancer requiring a stent to improve dysphagia will not benefit further from addition of concurrent palliative radiotherapy.

Article  PubMed  PubMed Central  Google Scholar 

Penniment MG, De Ieso PB, Harvey JA, et al. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). Lancet Gastroenterol Hepatol. 2018;3(2):114–24.

Article  PubMed  Google Scholar 

Lan K, Chen J. Efficacy and safety of re-irradiation for locoregional esophageal squamous cell carcinoma recurrence after radiotherapy: a systematic review and meta-analysis. Radiat Oncol. 2022;17(1):61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li RQ, Cao L, Zhao KL, et al. Progress in diagnosis and treatment of local recurrence after radical radiotherapy for esophageal cancer. Zhong Hua Fang She Zhong Liu Xue Za Zhi. 2016;9:1020–4.

Google Scholar 

•• Andratschke N, Willmann J, Appelt AL, et al. European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making. Lancet Oncol. 2022;23(10):e469–78. This reference is of major importance because it is the ESTRO-EORTC-endorsed consensus on classification of re-irradiation based on a Delphi process.

Article  PubMed  Google Scholar 

Nonoshita T, Sasaki T, Hirata H, et al. High-dose-rate brachytherapy for previously irradiated patients with recurrent esophageal cancer. Radiat Med. 2007;25:373–7.

Article  PubMed  Google Scholar 

Kim YS, Lee CG, Kim KH, et al. Re-irradiation of recurrent esophageal cancer after primary definitive radiotherapy. Radiat Oncol J. 2012;30:182–8.

Article  PubMed  PubMed Central  Google Scholar 

Zhou ZG, Zhen CJ, Bai WW, et al. Salvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy. Radiat Oncol. 2015;10:54.

Article  PubMed  PubMed Central  Google Scholar 

Hong L, Huang YX, Zhuang QY, et al. Survival benefit of re-irradiation in esophageal cancer patients with locoregional recurrence: a propensity score-matched analysis. Radiat Oncol. 2018;13:171.

Article  PubMed  PubMed Central  Google Scholar 

Wu X, Hu X, Chen J, et al. A re-irradiation dose of 55–60 Gy improves the survival rate of patients with local recurrent esophageal squamous cell carcinoma after radiotherapy. Radiat Oncol. 2021;16(1):100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao K, Si Y, Sun L, et al. Efficacy and toxicity of re-irradiation for esophageal cancer patients with locoregional recurrence: a retrospective analysis. Radiat Oncol. 2020;15:243.

Article  PubMed  PubMed Central  Google Scholar 

•• Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–28. This reference is of major importance because it is the system of characterization and classification of oligometastatic disease developed by ESTRO OligoCare project based on a Delphi process.

Article  PubMed  Google Scholar 

• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–8. This reference is of importance because is the international multicenter randomized phase II trial supporting that cancer patients with a controlled primary tumor and 1–5 oligometastases will benefit from stereotactic ablative radiotherapy.

Article  PubMed  Google Scholar 

Port JL, Nasar A, Lee PC, et al. Definitive therapy for isolated esophageal metastases prolongs survival. Ann Thorac Surg. 2012;94(2):413e20.

Article  Google Scholar 

Depypere L, Lerut T, Moons J, et al. Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road. Dis Esophagus. 2017;30(1):1e8.

Google Scholar 

Chen Y, Cheng X, Song H, et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases. J Thorac Dis. 2019;11(4):1536e45.

Article  Google Scholar 

Ghaly G, Harrison S, Kamel MK, et al. Predictors of survival after treatment of oligometastases after esophagectomy. Ann Thorac Surg. 2018;105(2):357e62.

Article  Google Scholar 

• Liu Q, Zhu Z, Chen Y, Deng J, Ai D, Liu Q, Wang S, Wu S, Chen J, Zhao K. Phase 2 Study of stereotactic body radiation therapy for patients with oligometastatic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2020;108(3):707–15. This reference is of importance because it is a phase II trial suggesting that stereotactic body radiation therapy is a well-tolerated and efficacious treatment modality for well-selected patients with oligometastatic esophageal squamous cell carcinoma.

Article  PubMed  Google Scholar 

• Kroese TE, van Laarhoven HWM, Nilsson M, et al. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: a systematic review and meta-analysis. Eur J Cancer. 2022;166:254–69. This reference is of importance because it is a systematic review according to PRISMA guidelines reporting on a definition of oligometastatic esophagogastric cancer.

Article  CAS  PubMed  Google Scholar 

Shi Z, Zhu X, Ke S, et al. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: a propensity score matching and landmark analyses. Radiother Oncol. 2021;164:236–44.

Article  PubMed  Google Scholar 

Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA: a cancer journal for clinicians. 2017;67(1):65–85. https://doi.org/10.3322/caac.21358.

Article  PubMed